As an exemplar of precision medicine, human epidermal growth factor receptor-2 (HER2)-targeted therapies have greatly improved the prognosis of HER2-Positive breast cancer patients; however, they have failed to do so in HER2-Negative patients according to several pivotal trials [2]. Here, ERBB2 is linked to breast cancer.